In patients with PAH, riociguat significantly improved exercise capacity and secondary efficacy endpoints, including improvement in 6-min walk distance, pulmonary vascular resistance, NT-proBNP levels, WHO functional class, time to clinical deterioration, and Borg dyspnea score. Here, NPPB is linked to pulmonary arterial hypertension.